CTMX Q3 2023 Earnings — CytomX Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CTMXCytomX Therapeutics, Inc.

$846M

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$26M+136.7% YoY

Gross Profit

$25M94.6% margin

Operating Income

$11M42.0% margin

Net Income

$3M11.3% margin

EPS (Diluted)

$0.04

QoQ Revenue Growth

+6.7%

Cash Flow

Operating Cash Flow

-$18M

Free Cash Flow

-$18M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$221M

Total Liabilities

$272M

Stockholders' Equity

-$51M

Cash & Equivalents

$26M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$26M	$11M	+136.7%
Gross Profit	$25M	$10M	+158.3%
Operating Income	$11M	-$30M	+137.3%
Net Income	$3M	-$29M	+110.3%